Iron Supplementation: Forms, Dosage Topical Map: SEO Clusters

Ferrous salts (ferrous sulfate, fumarate, gluconate) provide the highest elemental iron and are the most evidence-backed for efficacy; ferrous sulfate (325 mg = ~65 mg elemental) is commonly first-line. For poor tolerance, lower-elemental options (ferrous gluconate) or slow-release/enteric-coated formulations can reduce GI side effects but may lower absorption, and newer heme iron polypeptide or liposomal iron often show better tolerability with variable evidence of equivalent efficacy.

Typical treatment dosing for iron-deficiency anemia is 100–200 mg of elemental iron per day in divided doses (often 2–3 doses) or 60–120 mg elemental every other day for regimens aimed at improving absorption and tolerability. For prevention or maintenance, the RDA is 8 mg/day for adult men, 18 mg/day for nonpregnant women 19–50, and 27 mg/day in pregnancy (NIH values).

Common conversions: ferrous sulfate 325 mg ≈ 65 mg elemental iron, ferrous fumarate 300 mg ≈ 99 mg elemental iron, and ferrous gluconate 300 mg ≈ 35 mg elemental iron. Always check manufacturer labeling because formulations and elemental content vary.

Randomized and pharmacokinetic studies show alternate-day dosing (e.g., 60–120 mg elemental every other day) can increase fractional absorption by reducing hepcidin-mediated blockade and often causes fewer GI side effects, making it a reasonable strategy for many patients. However, in severe anemia or when rapid repletion is needed, daily dosing or IV iron may still be preferred.

Consider IV iron for patients with severe anemia needing rapid repletion, documented oral iron intolerance or nonadherence, malabsorption (e.g., post-gastric bypass, celiac), chronic kidney disease on dialysis, or ongoing blood loss where oral therapy fails. Modern IV formulations (iron sucrose, ferric carboxymaltose, iron dextran) allow larger single doses and typically resolve anemia faster than oral therapy.

Common side effects are GI: constipation, nausea, abdominal pain, and dark stools, affecting roughly 20–40% of users and a major cause of discontinuation. Strategies include taking a lower elemental dose, switching to alternate-day dosing, taking with small amounts of food (if needed for tolerance), using a different salt (gluconate or slow-release), or switching to heme/liposomal formulations or IV iron if intolerance persists.

Serious anaphylactic reactions with modern non-dextran IV iron formulations are rare (well under 0.1% in most surveillance data), though mild infusion reactions (flushing, chest tightness, transient myalgias) occur in a small percentage. Facilities administering IV iron should have protocols for monitoring and managing acute reactions and choose formulations based on patient risk and local availability.

Hemoglobin typically rises within 2–4 weeks of adequate therapy, with a rise of about 1–2 g/dL over 2–3 weeks common; complete repletion of iron stores often requires 3–6 months of continued therapy after hemoglobin normalizes. Monitoring should include hemoglobin at 2–4 weeks and ferritin/TSAT at 8–12 weeks to confirm repletion.

Calcium, antacids, and PPIs reduce oral iron absorption; separate dosing by 2–4 hours when possible or consider switching to alternate formulations/IV iron if interactions are unavoidable. For patients on chronic PPI therapy who need repletion, higher doses, alternate-day dosing, or IV iron are reasonable strategies because gastric acidity affects solubilization and uptake.

Monitor hemoglobin and reticulocyte response at 2–4 weeks to document a treatment response; check ferritin and transferrin saturation (TSAT) at 8–12 weeks to assess iron store repletion. For patients on chronic replacement or IV iron, periodic ferritin/TSAT and clinical assessment for iron overload are recommended based on the clinical context.